Albumin-targeting of an oxaliplatin-releasing platinum(<scp>iv</scp>) prodrug results in pronounced anticancer activity due to endocytotic drug uptake <i>in vivo</i>
Hemma Schueffl, Sarah Theiner, Gerrit Hermann, Josef Mayr, Philipp Fronik, Diana Groza, Sushilla van Schonhooven, Luis Galvez, Nadine S. Sommerfeld, Arno Schintlmeister, Siegfried Reipert, Michael Wagner, Robert M. Mader, Gunda Koellensperger, Bernhard K. Keppler, Walter Berger, Christian R. Kowol, Anton A. Legin, Petra Heffeter
Abstract
based on cell cycle arrest and apoptotic cell death. Summarizing, albumin-binding of platinum(iv) complexes potently enhances the efficacy of oxaliplatin therapy and should be further developed towards clinical phase I trials.
Topics & Concepts
ProdrugIn vivoOxaliplatinChemistryPharmacologyDrugAlbuminTargeted drug deliveryIn vitroBiochemistryMedicineCancerBiologyInternal medicineBiotechnologyColorectal cancerMetal complexes synthesis and propertiesCancer Treatment and PharmacologyNanoparticle-Based Drug Delivery